Q2 2026 · Form 13F LedgerData source: SEC EDGAR  
H

HOLDER.TOP

Who owns what — the quarterly ledger of U.S. institutional holdings.
EN · 简 · 繁
Funds / Elmind Capital, LP
Form 13F · Q2 2026

Elmind Capital, LP

CIK 2052213Filed 2026-08-1413F-HR View the filing on EDGAR ↗
$398M
Reported book value
35
Positions
3
Quarters on record
Top 50
Positions

Elmind Capital, LP — holdings

Top 35 positions of 35, ranked by reported value. Share change is versus the previous quarter.
#SecuritySharesShare Δ QoQValue% of book
1COGT Cogent Biosciences Inc1.2M+0.0%$45M11.4%
2SNDX Syndax Pharmaceuticals Inc1.9M+0.0%$41M10.2%
3CLDX Celldex Therapeutics Inc New990,000+14.5%$37M9.3%
4RLAY Relay Therapeutics Inc1.5M+172.9%$27M6.9%
5PCVX Vaxcyte Inc452,340+42.9%$26M6.6%
6VERA Vera Therapeutics Inc436,518−9.5%$19M4.7%
7PHVS Pharvaris N V525,750+10.5%$18M4.6%
8VRDN Viridian Therapeutics Inc984,931+84.1%$18M4.5%
9CTMX Cytomx Therapeutics Inc.4.5M+0.0%$17M4.3%
10TVTX Travere Therapeutics Inc292,600+64.8%$17M4.2%
11LEGN Legend Biotech Corp570,569—$16M4.1%
12BEAM Beam Therapeutics Inc476,338+0.0%$16M4.1%
13CGEM Cullinan Therapeutics Inc690,000+30.2%$13M3.2%
14NRIX Nurix Therapeutics Inc460,000+0.0%$11M2.8%
15KRYS Krystal Biotech Inc22,000+0.0%$8M2.1%
16UTHR United Therapeutics Corp Del15,000+0.0%$8M2.0%
17SMMT Summit Therapeutics Inc493,820—$7M1.8%
18INSM Insmed Inc65,000—$7M1.7%
19BCRX Biocryst Pharmaceuticals Inc520,000−48.0%$5M1.3%
20MBX Mbx Biosciences Inc91,000−56.9%$5M1.3%
21PTGX Protagonist Therapeutics Inc38,000+0.0%$5M1.2%
22URGN Urogen Pharma Ltd120,000−45.5%$4M1.1%
23DBVT Dbv Technologies S A265,000+0.0%$4M1.1%
24ALMS Alumis Inc130,000+0.0%$4M0.9%
25SUPN Supernus Pharmaceuticals70,000+250.0%$3M0.8%
26BMRN Biomarin Pharmaceutical Inc47,000+0.0%$3M0.7%
27IMCR Immunocore Hldgs Plc81,143+39.3%$3M0.6%
28AMLX Amylyx Pharmaceuticals Inc112,000+0.0%$2M0.5%
29ALEC Alector Inc900,000+0.0%$2M0.5%
30SEPN Septerna Inc49,444—$2M0.4%
31DSGN Design Therapeutics Inc107,900−48.1%$2M0.4%
32STRO Sutro Biopharma Inc32,037—$1M0.3%
33WVE Wave Life Sciences Ltd177,846+0.0%$1M0.3%
34TYRA Tyra Biosciences Inc20,000−94.3%$638,8000.2%
35ENGN Engene Therapeutics Inc210,000—$363,3000.1%
Source: Form 13F filings via SEC EDGAR. Positions as of Jun 30, 2026. Options (put/call) are excluded from share counts.